Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00979862 · ClinicalTrials.gov registry record · Phase 1
Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT00979862: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00979862 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 47 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00979862, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and best dose of cediranib maleate when given together with cilengitide in treating patients with progressive or recurrent glioblastoma. Cediranib maleate and cilengitide may stop the growth of tumor cells by blocking blood flow to the tumor. Giving cediranib maleate together with cilengitide may kill more tumor cells.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Cediranib Maleate
- DRUG Cilengitide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2010-03 |
| Est. Completion | 2014-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00979862
The ClinicalTrials.gov registry entry for NCT00979862 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT00979862 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00979862 about?
NCT00979862 is a clinical study titled "Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma". This phase I trial is studying the side effects and best dose of cediranib maleate when given together with cilengitide in treating patients with progressive or recurrent glioblastoma. Cediranib maleate and cilengitide may stop the growth of tumor cells by blocking blood flow to the tumor. Giving ce...
What is the current status of trial NCT00979862?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2010-03. Estimated completion is 2014-02.
What interventions are being tested in trial NCT00979862?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Cediranib Maleate (DRUG), Cilengitide (DRUG).
Who is sponsoring clinical trial NCT00979862?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.